KR20240121239A - 질환 치료를 위한 이환식 화합물의 용도 - Google Patents

질환 치료를 위한 이환식 화합물의 용도 Download PDF

Info

Publication number
KR20240121239A
KR20240121239A KR1020247019794A KR20247019794A KR20240121239A KR 20240121239 A KR20240121239 A KR 20240121239A KR 1020247019794 A KR1020247019794 A KR 1020247019794A KR 20247019794 A KR20247019794 A KR 20247019794A KR 20240121239 A KR20240121239 A KR 20240121239A
Authority
KR
South Korea
Prior art keywords
compound
alkyl
mmol
halo
membered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247019794A
Other languages
English (en)
Korean (ko)
Inventor
린 카와스
케빈 처치
로버트 테일러
쥬얼 존스톤
더글라스 보트만
Original Assignee
아티라 파마, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아티라 파마, 인코포레이티드 filed Critical 아티라 파마, 인코포레이티드
Publication of KR20240121239A publication Critical patent/KR20240121239A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020247019794A 2021-12-17 2022-12-16 질환 치료를 위한 이환식 화합물의 용도 Pending KR20240121239A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163290783P 2021-12-17 2021-12-17
US63/290,783 2021-12-17
US202263312696P 2022-02-22 2022-02-22
US63/312,696 2022-02-22
PCT/US2022/053113 WO2023114456A1 (en) 2021-12-17 2022-12-16 Uses of bicyclic compounds for the treatment of diseases

Publications (1)

Publication Number Publication Date
KR20240121239A true KR20240121239A (ko) 2024-08-08

Family

ID=86773494

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247019794A Pending KR20240121239A (ko) 2021-12-17 2022-12-16 질환 치료를 위한 이환식 화합물의 용도

Country Status (11)

Country Link
US (1) US20250041307A1 (https=)
EP (1) EP4448100A4 (https=)
JP (1) JP2024546600A (https=)
KR (1) KR20240121239A (https=)
AU (1) AU2022410646A1 (https=)
CA (1) CA3240896A1 (https=)
CL (1) CL2024001748A1 (https=)
IL (1) IL313039A (https=)
MX (1) MX2024005884A (https=)
TW (1) TW202339756A (https=)
WO (1) WO2023114456A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025515045A (ja) * 2022-05-04 2025-05-13 アティラ・ファーマ・インコーポレイテッド 神経炎症病態を治療する方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184223B1 (en) * 1995-10-27 2001-02-06 Molecumetics Ltd. Reverse-turn mimetics and methods relating thereto
AU2003284120A1 (en) * 2002-10-17 2004-05-04 Myriad Genetics, Inc. Reverse-turn mimetics and composition and methods relating thereto
EP2155226A4 (en) * 2007-06-14 2010-07-28 Univ California COMPOUNDS FOR INHIBITING THE PROTEIN AGGREGATION AND METHOD FOR THE PRODUCTION AND USE THEREOF
KR20130139895A (ko) * 2010-09-02 2013-12-23 다케다 야쿠힌 고교 가부시키가이샤 경도인지 장애의 치료 또는 예방용 융합 트리아졸
CA2817975C (en) * 2010-11-16 2020-03-31 Michael Kahn Cbp/catenin antagonists for enhancing asymmetric division of somatic stem cells
AP2014007606A0 (en) * 2011-10-07 2014-05-31 Takeda Pharmaceutical 1-Arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases
CN119684295A (zh) * 2020-11-02 2025-03-25 雅斯娜制药公司 用于治疗疾病的双环化合物及其用途

Also Published As

Publication number Publication date
CL2024001748A1 (es) 2024-11-22
WO2023114456A1 (en) 2023-06-22
TW202339756A (zh) 2023-10-16
CA3240896A1 (en) 2023-06-22
EP4448100A4 (en) 2025-10-22
US20250041307A1 (en) 2025-02-06
IL313039A (en) 2024-07-01
MX2024005884A (es) 2024-05-29
AU2022410646A1 (en) 2024-05-30
JP2024546600A (ja) 2024-12-26
EP4448100A1 (en) 2024-10-23

Similar Documents

Publication Publication Date Title
JP2026067870A (ja) Ｎｅｋ７キナーゼの阻害剤
KR20230104191A (ko) 질환 치료를 위한 이환식 화합물 및 그 용도
AU2022255486A1 (en) Nek7 inhibitors
KR20240121239A (ko) 질환 치료를 위한 이환식 화합물의 용도
KR20250005230A (ko) 신경염증성 병태를 치료하는 방법
EP4598907A1 (en) Phenyl oxy amide kinase inhibitors
TWI918751B (zh) 用於治療疾病之雙環化合物及其用途
CN118382441A (zh) 双环化合物用于治疗疾病的用途
KR20250005323A (ko) 신경병증을 치료하는 방법
HK40113746A (zh) 双环化合物用於治疗疾病的用途
EA049703B1 (ru) Бициклические соединения и их применение для лечения заболеваний
EA050745B1 (ru) Применение бициклических соединений для лечения заболеваний
HK40122844A (zh) 用於治疗疾病的双环化合物及其用途
HK40097563A (zh) 用於治疗疾病的双环化合物及其用途

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R11-ASN-PN2301 (AS PROVIDED BY THE NATIONAL OFFICE)

R13 Change to the name of applicant or owner recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R13-ASN-PN2301 (AS PROVIDED BY THE NATIONAL OFFICE)